I-Mab
-
Everest Medicines has strategically increased its stake in I-Mab, becoming its largest shareholder
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
-
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
For more DrugTimes bio-news, please follow DrugTimes. Many thanks!
-
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
For more bio-news, please follow DrugTimes. Many thanks!
-
180万美元预付款！I-Mab收购Bridge Health
全文共919字 预计阅读时间：5分钟 2025 年 7 月 17 日，专注于精准免疫肿瘤药物研发的全球性生物技术公司I-Mab宣布达成最终协议，收购Bridge Health Bi…
